The primary tumor location in colorectal cancer: A focused review on its impact on surgical management.
Primary tumor location
colorectal cancer
surgery
Journal
Global health & medicine
ISSN: 2434-9194
Titre abrégé: Glob Health Med
Pays: Japan
ID NLM: 101771579
Informations de publication
Date de publication:
31 Dec 2021
31 Dec 2021
Historique:
received:
24
10
2020
revised:
30
05
2021
accepted:
14
06
2021
entrez:
17
1
2022
pubmed:
18
1
2022
medline:
18
1
2022
Statut:
ppublish
Résumé
The primary tumor location (PTL) has attracted increasing attention in recent years for colorectal cancer (CRC) patients. Although the underlying mechanisms for differences caused by PTL remain still unclear, right-sided colon (RCC) and left-sided colon (LCC) are now considered as distinct entities because of their different molecular profile and clinical response to surgery and chemotherapy. In this article, we review the influence of PTL particularly on surgical management of primary and metastatic CRC settings. For nonmetastatic CRC, RCC could be a slightly superior prognostic factor after curative resection in stage I-II CRC, while RCC could be an inferior prognostic factor in stage III CRC with worse survival after recurrence, suggesting the oncological aggressiveness of recurrent RCC. For metastatic CRC, RCC could be a predictor of worse survival after hepatectomy of liver metastases from CRC with aggressive recurrence pattern and lower chance of re-resection. In lung metastases from CRC, the role of PTL still remains uncertain because of the limited number of studies. As to the impact of PTL on survival outcome after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from CRC, a discrepancy exists among studies and further investigation will be needed. The very simple clinical factor of PTL could provide important information for the prediction of the survival outcome after surgery in CRC. Further clinical and basic research will facilitate the clinical application of PTL in a more specified and personalized manner.
Identifiants
pubmed: 35036620
doi: 10.35772/ghm.2020.01096
pmc: PMC8692095
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
386-393Informations de copyright
2021, National Center for Global Health and Medicine.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Cancers (Basel). 2020 Aug 20;12(9):
pubmed: 32825275
J Thorac Cardiovasc Surg. 2021 Jul;162(1):296-305
pubmed: 32713636
J Surg Oncol. 2020 Jun 10;:
pubmed: 32524637
Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7
pubmed: 15166961
JAMA Oncol. 2017 Jul 13;3(7):e170278
pubmed: 28542671
J Gastroenterol. 2020 Oct;55(10):958-968
pubmed: 32651860
Cancers (Basel). 2020 Jun 20;12(6):
pubmed: 32575781
Eur J Cancer. 2019 Apr;111:1-7
pubmed: 30797014
Anticancer Res. 2016 Jan;36(1):13-9
pubmed: 26722023
Cell Mol Gastroenterol Hepatol. 2017 Jan 20;3(2):163-173
pubmed: 28275683
Medicine (Baltimore). 2018 Mar;97(9):e0019
pubmed: 29489646
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Cancer Med. 2020 Jul;9(14):5221-5234
pubmed: 32452655
JAMA Oncol. 2017 Feb 1;3(2):194-201
pubmed: 27722750
ANZ J Surg. 2020 Sep;90(9):1592-1597
pubmed: 32129577
Clin Exp Metastasis. 2015 Jun;32(5):457-65
pubmed: 25899064
Int J Clin Oncol. 2020 Jan;25(1):1-42
pubmed: 31203527
Ann Surg. 2018 May;267(5):917-921
pubmed: 28272099
Ann Oncol. 2017 Aug 1;28(8):1862-1868
pubmed: 28449055
Interact Cardiovasc Thorac Surg. 2016 Dec;23(6):962-969
pubmed: 27572615
Ann Surg Oncol. 2020 May;27(5):1580-1588
pubmed: 31792717
Ann Oncol. 2020 Oct;31(10):1291-1305
pubmed: 32702383
Gut. 2012 Jun;61(6):847-54
pubmed: 22427238
J Natl Compr Canc Netw. 2017 Mar;15(3):411-419
pubmed: 28275039
Surgery. 2019 Feb;165(2):476-484
pubmed: 30197280
J Gastrointest Surg. 2020 Aug;24(8):1833-1842
pubmed: 31313144
Expert Rev Anticancer Ther. 2012 Apr;12(4):495-503
pubmed: 22500686
Ann Surg Oncol. 2008 Sep;15(9):2388-94
pubmed: 18622647
Tech Coloproctol. 2019 Jun;23(6):537-544
pubmed: 31190234
Crit Rev Oncol Hematol. 2018 Jul;127:105-116
pubmed: 29891107
Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51
pubmed: 15570209
Eur J Surg Oncol. 2019 Aug;45(8):1349-1356
pubmed: 31054852
Dis Colon Rectum. 2003 Oct;46(10 Suppl):S22-31
pubmed: 14530655
Lancet Oncol. 2016 Nov;17(11):1480-1482
pubmed: 27819229
World J Gastroenterol. 2010 Jul 14;16(26):3318-24
pubmed: 20614489
BMC Gastroenterol. 2019 Mar 27;19(1):46
pubmed: 30917791
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Gastroenterology Res. 2018 Aug;11(4):264-273
pubmed: 30116425
J Surg Res. 2020 Apr;248:20-27
pubmed: 31841733
Br J Surg. 2019 Dec;106(13):1747-1760
pubmed: 31386192
J Cancer. 2019 Feb 26;10(7):1593-1600
pubmed: 31205514
Cancer Med. 2020 Aug;9(16):5851-5859
pubmed: 32614506
Ann Surg Oncol. 2019 Jul;26(7):2234-2240
pubmed: 31016486
HPB (Oxford). 2020 Jan;22(1):116-123
pubmed: 31235431
Ann Surg Oncol. 2019 May;26(5):1421-1427
pubmed: 30815802